Clinical News from the American Society of Haematology (‘ASH’)16 Aug. 2022
The American Society of Haematology (ASH) have published some very interesting articles about various aspects of MDS and the potential effectiveness of a number of treatments (see the links below).
The hematopoietic cell architecture in myelodysplastic syndromes (MDS) may have the potential to predict disease progression and guide use of second-line treatment...Read more
The presence of ASXL1 mutations predicted a favourable response and survival after venetoclax and hypomethylating agent (HMA) therapy in patients with MDS with excess blasts (EB)...Read More
Patients with higher risk myelodysplastic syndromes (MDS) were treated with magrolimab plus azacitidine in a phase Ib study. Investigators noted a lower-than-expected rate of discontinuation due to adverse events (AEs)...Read more